Cancer drug approvals and setbacks in 2021

Asher Milliard

首页> 外文期刊>Nature cancer. >Cancer drug approvals and setbacks in 2021

【24h】

Cancer drug approvals and setbacks in 2021

机译：2021年癌症药物的批准和挫折

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

From a first-in-class KRAS approval to the latest agonist antibody failures, 2021 was another busy year for cancer drug developers. The cancer pipeline is a crowded place. The US Food and Drug Administration (FDA) has already approved more than a dozen new cancer drugs this year. Hundreds more have entered the clinic. Here are some of the approvals, regulatory challenges and trial failures that caught our eye.

机译：从first-in-class喀斯特最新批准受体激动剂的抗体失败,2021年是另一个忙抗癌药物的开发人员。管道是一个拥挤的地方。管理局(FDA)已经批准了今年的十几个新癌症药物。更多的进入诊所。批准,监管挑战和审判失败吸引我们的眼球。

著录项

来源
《Nature cancer.》 |2021年第12期|1246-1247|共2页
作者
Asher Milliard;
展开▼
作者单位

Science journalist, Ottawa, Ontario, Canada.;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类
关键词
Antineoplastic Agents; approval; CrowdingEye;

机译：抗肿瘤药制剂;批准;CrowdingEye;

相似文献

外文文献
中文文献
专利

1. A Review of CDER's Novel Drug Approvals for 2016 [J] . John Jenkins 中国药学（英文版） . 2017,第002期
2. Successful generic drug product development:From research to marketing approval [J] . Suchart Chongprasert 亚洲药物制剂科学(英文) . 2016,第001期
3. Astellas, Aurobindo to Drop Patent Fight Over Xtandi Cancer Drug [J] . By Christopher Yasiejko Bloomberg Law IP Law News . 2019,第Sepa5期

机译：Astellas，Aurobindo放弃Xtandi Cancer Drug的专利斗争
4. Lilly Wins Appeal Upholding Patent on Alimta Cancer Drug (1) [J] . Bloomberg Law IP Law News . 2019,第Apra29期

机译：礼来赢得上诉维持Alimta Cancer Drug的专利（1）
5. Sanofi Wins Ruling Blocking Cadila’s Copy of Mozobil Cancer Drug [J] . Bloomberg Law IP Law News . 2018,第Auga23期

机译：赛诺菲赢得了统治阻塞Cadila的Mozobil Cancer Drug副本
6. Where is My Lab Dip? How One Quality-Focused Brand Made the Leap to E-Approvals [C] . Eva Reale American Association of Textile Chemists and Colorists International Conference . 2018

机译：我的实验室划分在哪里？一个以质量为中心的品牌如何实现了E-Approvals的飞跃
7. Engineering Multifunctional Mesoporous Silica Nanoparticles for Stimuli-responsive Drug Delivery and Bioimaging =設計多功能介孔二氧化矽奈米粒子--用於刺激反應性藥物遞送和生物成像 [D] . Cheng, Chi-An. 2020

机译：Engineering Multifunctional Mesoporous Silica Nanoparticles for Stimuli-responsive Drug Delivery and Bioimaging =设计多功能介孔二氧化矽奈米粒子--用于刺激反应性药物递送和生物成像
8. Correction to: Cancer Biother Radiopharm 2014;29(8):303–309. DOI: 10.1089/cbr.2014.1653 and Cancer Biother Radiopharm 2014;29(10):451–456. DOI: 10.1089/cbr.2014.1698 [O] . -1

机译：更正为：Cancer Biother Radiopharm 2014; 29（8）：303-309。 DOI：10.1089 / cbr.2014.1653和Cancer Biother Radiopharm 2014; 29（10）：451–456。 DOI：10.1089 / cbr.2014.1698
9. Folate and iron difunctionalized multiwall carbon nanotubes as dual-targeted drug nanocarrier to cancer cells [O] . Li Ruibin, Wu Renan, Zhao Liang, 2011

机译：Folate and iron difunctionalized multiwall carbon nanotubes as dual-targeted drug nanocarrier to cancer cells
10. Tratamiento para el Cancer de Prostata: Guia para Hombres con Cancer Localizado de Prostata (Treating Prostate Cancer: A Guide for Men with Localized Prostate Cancer). [R] . 2008

机译：Tratamiento para el Cancer de prostata：Guia para Hombres con Cancer Localizado de prostata（治疗前列腺癌：患有局部前列腺癌的男性指南）。

Cancer drug approvals and setbacks in 2021

摘要

著录项

相似文献

相关主题

期刊订阅